CHILDHOOD OSTEOPOROSIS AND PRESENTATION OF TWO CASES WITH OSTEOGENESIS IMPERFECTA TYPE V

被引:2
|
作者
Bratanic, Nina [1 ]
Dzodan, Bojana [1 ]
Trebusak Podkrajsek, Katarina [2 ,4 ]
Bertok, Sara [1 ]
Ostanek, Barbara [3 ]
Marc, Janja [3 ]
Battelino, Tadej [1 ,4 ]
Avbelj Stefanija, Magdalena [1 ]
机构
[1] Univ Childrens Hosp, Dept Pediat Endocrinol Diabet & Metab Dis, Ljubljana 1000, Slovenia
[2] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Unit Special Lab Diagnost, Ljubljana 1000, Slovenia
[3] Univ Ljubljana, Fac Farmacy, Ljubljana 1000, Slovenia
[4] Univ Ljubljana, Fac Med, Ljubljana 1000, Slovenia
来源
ZDRAVSTVENO VARSTVO | 2015年 / 54卷 / 02期
关键词
bone mineral density; hypertrophic callus; IFITM5; gene; bisphosphonates; HYPERPLASTIC CALLUS FORMATION; BISPHOSPHONATE THERAPY; PHENOTYPIC VARIABILITY; FOLLOW-UP; MUTATION; CHILDREN; FRACTURES; POLYMORPHISM; ADOLESCENTS; PAMIDRONATE;
D O I
10.1515/sjph-2015-0018
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction. Osteogenesis imperfecta (OI) is etiologically heterogeneous disorder characterized by childhood osteoporosis. A subtype OI type V is caused by the same c.-14C>T mutation in the IFITM5 gene. Nevertheless, there is a marked interindividual phenotypic variability in clinical presentation; however, response to bisphosphonates is reported to be good. Methods. Two individuals with OI type V had multiple recurrent fractures with hypertrophic calluses, scoliosis and ossifications of the forearm interosseous membranes. Sequencing of IFITM5, genotyping of variants rs2297480 in farnesyl diphosphate synthase gene (FDPS), and rs3840452 in geranylgeranyl diphosphate synthase 1 gene (GGPS1), both involved in bisphosphonate metabolism, was performed. Results. In patient 1 BMD reached normal values during bisphosphonate treatment and remained normal four years after the treatment discontinuation. In patient 2 no increase in BMD after five years of bisphosphonate treatment was observed and callus formation continued. The c.-14C>T IFITM5 mutation in heterozygous state was detected in both individuals. Additionally, both patients carried FDPS variant rs2297480 in homozygous state, and were heterozygous for GGPS 1 variant rs3840452. Conclusions. The paper presents a short overview of childhood osteoporosis with a special emphasis on OI type V by presenting two cases. Both OI type V patients had identical disease-causing mutation, but marked interindividual phenotypic variability. The striking failure in response to bisphosphonate treatment in one of the patients could not be explained by the variants in genes involved in bisphosphonate metabolism.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [31] Accelerated mineralization kinetics in children with osteogenesis imperfecta type 1
    Misof, Barbara M.
    Roschger, Paul
    Maehr, Matthias
    Fratzl-Zelman, Nadja
    Glorieux, Francis H.
    Hartmann, Markus A.
    Rauch, Frank
    Blouin, Stephane
    BONE, 2023, 166
  • [32] Phenotypic Variability of Osteogenesis Imperfecta Type V Caused by an IFITM5 Mutation
    Shapiro, Jay R.
    Lietman, Caressa
    Grover, Monica
    Lu, James T.
    Nagamani, Sandesh C. S.
    Dawson, Brian C.
    Baldridge, Dustin M.
    Bainbridge, Matthew N.
    Cohn, Dan H.
    Blazo, Maria
    Roberts, Timothy T.
    Brennen, Feng-Shu
    Wu, Yimei
    Gibbs, Richard A.
    Melvin, Pamela
    Campeau, Philippe M.
    Lee, Brendan H.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (07) : 1523 - 1530
  • [33] Response to zolendronic acid in children with type III osteogenesis imperfecta
    Panigrahi, Inusha
    Das, Rashmi Ranjan
    Sharda, Sheetal
    Marwaha, Ram Kumar
    Khandelwal, Niranjan
    JOURNAL OF BONE AND MINERAL METABOLISM, 2010, 28 (04) : 451 - 455
  • [34] Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta
    Kanno, Junko
    Saito-Hakoda, Akiko
    Kure, Shigeo
    Fujiwara, Ikuma
    JOURNAL OF BONE AND MINERAL METABOLISM, 2018, 36 (03) : 344 - 351
  • [35] Phenotype and Genotype Analysis of Chinese Patients with Osteogenesis Imperfecta Type V
    Zhang, Zeng
    Li, Mei
    He, Jin-Wei
    Fu, Wen-Zhen
    Zhang, Chang-Qing
    Zhang, Zhen-Lin
    PLOS ONE, 2013, 8 (08):
  • [36] Osteogenesis Imperfecta Type IIA
    Mittal, Aliza
    Sureka, Binit
    Bansal, Neha
    Chellani, Harish
    JOURNAL OF CLINICAL NEONATOLOGY, 2015, 4 (01) : 60 - 61
  • [37] Type V osteogenesis imperfecta: A new form of brittle bone disease
    Glorieux, FH
    Rauch, F
    Plotkin, H
    Ward, L
    Travers, R
    Roughley, P
    Lalic, L
    Glorieux, DF
    Fassier, F
    Bishop, NJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (09) : 1650 - 1658
  • [38] How frequent is osteogenesis imperfecta in patients with idiopathic osteoporosis? Case reports
    Al Kaissi, Ali
    Windpassinger, Christian
    Ben Chehida, Farid
    Ben Ghachem, Maher
    Nassib, Nabil M.
    Kenis, Vladimir
    Melchenko, Eugene
    Morenko, Ekatrina
    Ryabykh, Sergey
    Hofstaetter, Jochen G.
    Grill, Franz
    Ganger, Rudolf
    Kircher, Susanne Gerit
    MEDICINE, 2017, 96 (35)
  • [39] A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood
    Feehan, Andrew G.
    Zacharin, Margaret R.
    Lim, Angelina S.
    Simm, Peter J.
    BONE, 2018, 113 : 137 - 143
  • [40] Beyond Osteogenesis Imperfecta: Causes of Fractures During Infancy and Childhood
    Bronicki, Lucas M.
    Stevenson, Roger E.
    Spranger, Juergen W.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2015, 169 (04) : 314 - 327